Sartorius Stedim stock holds steady as analysts see upside potential

Published on 09/14/2026 at 23:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock is trading around EUR 184.30 as of September 14, 2026, with analysts’ average price target at EUR 240. Recent ratings from Berenberg, Barclays and UBS underline a constructive view on the biotech supplier.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech SA (ISIN FR0013154002) stock is quoted around EUR 184.30 as of September 14, 2026, while the average analyst price target stands at EUR 240, implying roughly 30 percent upside from current levels according to an overview on Sartorius Stedim Biotech SA compiled by FinanzNachrichten.

Analysts see room for gains

The latest sector overview dated September 14, 2026 lists Sartorius Stedim Biotech SA with a current price of EUR 184.30 and an average price target of EUR 240, which corresponds to a potential gain of 30 percent if the stock were to reach that target according to FinanzNachrichten.

In the same data set, seven analyst recommendations on Sartorius Stedim Biotech SA are categorized as buy, one as hold and none as sell, underlining that most houses currently take a positive stance on the shares, again based on the overview from FinanzNachrichten.

Recent rating actions on Sartorius

A detailed analyst summary for Sartorius, which also covers Sartorius Stedim, shows a series of rating confirmations and adjustments over recent weeks, including a buy rating from Joh. Berenberg, Gossler & Co. KG on September 11, 2026 and an overweight rating from Barclays Capital on September 8, 2026 according to finanzen.net.

The same overview also cites a buy recommendation from UBS AG on August 20, 2026 and a sector perform rating from RBC Capital Markets on August 12, 2026, as well as an outperform rating from Bernstein Research on July 30, 2026, underscoring that while the majority of ratings are positive, there are also more neutral views according to data presented by finanzen.net.

Stock level and investor perspective

At a price of roughly EUR 184.30 as of September 14, 2026, Sartorius Stedim stock trades below the average analyst price target of EUR 240 identified in the sector comparison by FinanzNachrichten, a gap that many investors will watch as they weigh the upside against the risks in the biotech supply segment.